GlassScriptPhysician profile
Joseph L Parisi
NPI 1760451892
$35,446.05
in general payments reported to CMS, 2019-2025
31 companies · $5,974 in 2025
The $5,974 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,889 · 2020: $4,584 · 2021: $6,128 · 2022: $8,105 · 2023: $2,561 · 2024: $4,205 · 2025: $5,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,925 · Consulting Fee: $2,965 · Travel and Lodging: $1,833 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,924.77 |
| Consulting Fee | $2,965.00 |
| Travel and Lodging | $1,832.70 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $11,689.40 | 2019-2025 | Clareon, Acrysof Iq Panoptix Uv Iol, Acrysof Iq Vivity |
| Carl Zeiss Meditec, INC. | $8,252.69 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $5,747.83 | 2022-2023 | Miebo |
| Biotissue Holdings INC. | $2,251.43 | 2023-2025 | |
| Carl Zeiss Meditec USA, INC. | $2,047.98 | 2021-2025 | Veracity Surgical, Quatera 700 |
| Glaukos Corporation | $749.10 | 2019-2025 | Idosetr, Istent Infinite, Idose |
| Rxsight INC | $633.49 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Allergan, INC. | $582.92 | 2019-2022 | |
| Ivantis, INC | $530.28 | 2019-2021 | |
| Sight Sciences, INC. | $323.27 | 2021-2024 | Omni Surgical System |
| Abbvie INC. | $305.97 | 2022-2025 | |
| Ocular Therapeutix, INC. | $295.05 | 2021-2024 | Dextenza |
| Lensar, INC. | $234.84 | 2023 | Lensar Laser System |
| Rayner Intraocular Lenses Limited | $228.51 | 2023-2025 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Johnson & Johnson Surgical Vision, INC. | $184.33 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tearlab Corp | $174.24 | 2019 | |
| Quidel Corporation | $167.22 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $156.22 | 2019-2022 | |
| Staar Surgical Company | $134.96 | 2019 | |
| Oyster Point Pharma, INC. | $128.55 | 2023-2025 | Tyrvaya |
| Horizon Therapeutics Plc | $120.00 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $107.50 | 2019-2021 | |
| Merz North America, INC. | $82.49 | 2021 | |
| Amgen INC. | $81.85 | 2024-2025 | Tepezza |
| Omeros Corporation | $60.88 | 2019-2020 | |
| Galderma Laboratories, L.P. | $50.72 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $47.79 | 2025 | Xdemvy |
| Shire North American Group INC | $30.49 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Harrow Eye, LLC | $15.66 | 2024 | |
| Carl Zeiss Meditec Digital Innovations LLC | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Parisi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.